ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc announces the allotment of 1,023,826 new ordinary shares following the exercise of options by CEO Andrew Newland. The shares were sold at 125 pence each for personal financial reasons. After the sale, Newland retains 7,054,686 shares, equating to 3.0% of the total issued share capital, alongside options for an additional 3,000,000 shares and up to 5,400,000 through performance plans. The total number of shares in issue will rise to 234,181,384 upon the new shares' admission on July 14, 2021.

ANGLE plc (AIM:AGL OTCQX:ANPCY), a leader in liquid biopsy technology, has issued 48,333 new Ordinary shares due to employee option exercises. This issuance increases the total shares to 233,157,558, enhancing voting rights. The shares are expected to be admitted to trading on the London Stock Exchange on July 7, 2021. ANGLE's Parsortix technology continues to gain traction, with ongoing FDA submission for CTC analysis in breast cancer and strong clinical performance in ovarian cancer diagnostics.

ANGLE plc announced the results of its Annual General Meeting held on June 30, 2021, where all resolutions were passed. The company, known for its innovative liquid biopsy technology, is progressing with the Parsortix system, which has received CE Mark approval in Europe and is awaiting FDA clearance in the U.S. for metastatic breast cancer applications. ANGLE's ongoing clinical studies show promising results, including a recent ovarian cancer test with an accuracy rate of 95.1%. Their technology aims to enhance cancer diagnostics through non-invasive methods.

ANGLE plc (AIM:AGL OTCQX:ANPCY) announces its Annual General Meeting (AGM) will take place on June 30, 2021, at 2:00 PM in Guildford, UK, as a closed meeting due to COVID-19 restrictions. Only two shareholders are required for a quorum, with executive members attending in person and others remotely. Voting will be online via proxy, and shareholders must register in advance to attend online. A business update will follow the AGM, and questions can be submitted to the Board in advance. The Annual Report was distributed to shareholders on June 4, 2021.

ANGLE plc has announced a pivotal study revealing significant differences in EGFR mutations between circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients. Conducted by a research team from the University of Athens, this study highlights the importance of analyzing CTCs for better treatment decisions. The results indicate CTCs can provide real-time insights into tumor evolution and resistance, unlike ctDNA, which offers historical data. This research underscores the potential of liquid biopsies in safer, cost-effective monitoring of cancer progression.

ANGLE plc (OTCQX:ANPCY) has confirmed the completion of its response to the FDA's Additional Information Request regarding the Parsortix system, a liquid biopsy technology. The comprehensive response has been submitted as planned, and the company expects a regulatory decision during H2 2021. The Parsortix system aims to become the first FDA-cleared device for harvesting circulating tumor cells (CTCs), enhancing cancer diagnostics. The De Novo process entails inherent uncertainties regarding timing and success, yet ANGLE remains optimistic about the FDA's review outcome.

ANGLE plc announces promising research from Washington University School of Medicine demonstrating the effectiveness of the Parsortix system in isolating rare cancer cells from breast cancer patients' bone marrow. This breakthrough could enhance the identification of biomarkers, leading to targeted treatments that may prevent relapse in patients in remission. With breast cancer affecting 3.7 million women in the US, the research indicates Parsortix's potential to eradicate dormant Disseminated Tumor Cells (DTCs) and improve patient outcomes.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announced the issuance of 216,000 new Ordinary shares following the exercise of employee options. These shares will rank equally with existing shares. An application for their trading admission on AIM has been submitted, with trading anticipated to begin on 24 May 2021. Post-admission, the total number of Ordinary Shares will stand at 215,867,845. The company continues to develop its liquid biopsy technology, particularly the Parsortix system, which has shown promise in clinical studies for cancer diagnostics.